Drug Discovery Outsourcing Market Size, Share, and Trends 2024 to 2034

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Drug Discovery Outsourcing Market 

5.1. COVID-19 Landscape: Drug Discovery Outsourcing Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Drug Discovery Outsourcing Market, By Workflow

8.1. Drug Discovery Outsourcing Market, by Workflow Type, 2022-2030

8.1.1. Target Identification & Screening

8.1.1.1. Market Revenue and Forecast (2019-2030)

8.1.2. Lead Identification & Candidate Optimization

8.1.2.1. Market Revenue and Forecast (2019-2030)

8.1.3. Target Validation & Functional Informatics

8.1.3.1. Market Revenue and Forecast (2019-2030)

8.1.4. Preclinical Development

8.1.4.1. Market Revenue and Forecast (2019-2030)

8.1.5. Others

8.1.5.1. Market Revenue and Forecast (2019-2030)

Chapter 9. Global Drug Discovery Outsourcing Market, By Therapeutic Area

9.1. Drug Discovery Outsourcing Market, by Therapeutic Area, 2022-2030

9.1.1. Oncology

9.1.1.1. Market Revenue and Forecast (2019-2030)

9.1.2. Cardiovascular

9.1.2.1. Market Revenue and Forecast (2019-2030)

9.1.3. Gastrointestinal

9.1.3.1. Market Revenue and Forecast (2019-2030)

9.1.4. Neurology

9.1.4.1. Market Revenue and Forecast (2019-2030)

9.1.5. Respiratory

9.1.5.1. Market Revenue and Forecast (2019-2030)

9.1.6. Others

9.1.6.1. Market Revenue and Forecast (2019-2030)

Chapter 10. Global Drug Discovery Outsourcing Market, By Drug Type 

10.1. Drug Discovery Outsourcing Market, by Drug Type, 2022-2030

10.1.1. Biologics

10.1.1.1. Market Revenue and Forecast (2019-2030)

10.1.2. Small Molecules

10.1.2.1. Market Revenue and Forecast (2019-2030)

Chapter 11. Global Drug Discovery Outsourcing Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Forecast, by Workflow (2019-2030)

11.1.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)

11.1.3. Market Revenue and Forecast, by Drug Type (2019-2030)

11.1.4. U.S.

11.1.4.1. Market Revenue and Forecast, by Workflow (2019-2030)

11.1.4.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)

11.1.4.3. Market Revenue and Forecast, by Drug Type (2019-2030)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Forecast, by Workflow (2019-2030)

11.1.5.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)

11.1.5.3. Market Revenue and Forecast, by Drug Type (2019-2030)

11.2. Europe

11.2.1. Market Revenue and Forecast, by Workflow (2019-2030)

11.2.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)

11.2.3. Market Revenue and Forecast, by Drug Type (2019-2030)

11.2.4. UK

11.2.4.1. Market Revenue and Forecast, by Workflow (2019-2030)

11.2.4.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)

11.2.4.3. Market Revenue and Forecast, by Drug Type (2019-2030)

11.2.5. Germany

11.2.5.1. Market Revenue and Forecast, by Workflow (2019-2030)

11.2.5.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)

11.2.5.3. Market Revenue and Forecast, by Drug Type (2019-2030)

11.2.6. France

11.2.6.1. Market Revenue and Forecast, by Workflow (2019-2030)

11.2.6.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)

11.2.6.3. Market Revenue and Forecast, by Drug Type (2019-2030)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Forecast, by Workflow (2019-2030)

11.2.7.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)

11.2.7.3. Market Revenue and Forecast, by Drug Type (2019-2030)

11.3. APAC

11.3.1. Market Revenue and Forecast, by Workflow (2019-2030)

11.3.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)

11.3.3. Market Revenue and Forecast, by Drug Type (2019-2030)

11.3.4. India

11.3.4.1. Market Revenue and Forecast, by Workflow (2019-2030)

11.3.4.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)

11.3.4.3. Market Revenue and Forecast, by Drug Type (2019-2030)

11.3.5. China

11.3.5.1. Market Revenue and Forecast, by Workflow (2019-2030)

11.3.5.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)

11.3.5.3. Market Revenue and Forecast, by Drug Type (2019-2030)

11.3.6. Japan

11.3.6.1. Market Revenue and Forecast, by Workflow (2019-2030)

11.3.6.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)

11.3.6.3. Market Revenue and Forecast, by Drug Type (2019-2030)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Forecast, by Workflow (2019-2030)

11.3.7.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)

11.3.7.3. Market Revenue and Forecast, by Drug Type (2019-2030)

11.4. MEA

11.4.1. Market Revenue and Forecast, by Workflow (2019-2030)

11.4.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)

11.4.3. Market Revenue and Forecast, by Drug Type (2019-2030)

11.4.4. GCC

11.4.4.1. Market Revenue and Forecast, by Workflow (2019-2030)

11.4.4.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)

11.4.4.3. Market Revenue and Forecast, by Drug Type (2019-2030)

11.4.5. North Africa

11.4.5.1. Market Revenue and Forecast, by Workflow (2019-2030)

11.4.5.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)

11.4.5.3. Market Revenue and Forecast, by Drug Type (2019-2030)

11.4.6. South Africa

11.4.6.1. Market Revenue and Forecast, by Workflow (2019-2030)

11.4.6.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)

11.4.6.3. Market Revenue and Forecast, by Drug Type (2019-2030)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Forecast, by Workflow (2019-2030)

11.4.7.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)

11.4.7.3. Market Revenue and Forecast, by Drug Type (2019-2030)

11.5. Latin America

11.5.1. Market Revenue and Forecast, by Workflow (2019-2030)

11.5.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)

11.5.3. Market Revenue and Forecast, by Drug Type (2019-2030)

11.5.4. Brazil

11.5.4.1. Market Revenue and Forecast, by Workflow (2019-2030)

11.5.4.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)

11.5.4.3. Market Revenue and Forecast, by Drug Type (2019-2030)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Forecast, by Workflow (2019-2030)

11.5.5.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)

11.5.5.3. Market Revenue and Forecast, by Drug Type (2019-2030)

Chapter 12. Company Profiles

12.1. Albany Molecular Research Inc.

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. EVOTEC

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Laboratory Corporation of America Holdings

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. GenScript

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. Pharmaceutical Product Development, LLC.

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. Charles River

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. WuXiAppTec

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. Merck & Co., Inc.

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. Thermo Fisher Scientific Inc.

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. Dalton Pharma Services

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

12.11. Oncodesign

12.11.1. Company Overview

12.11.2. Product Offerings

12.11.3. Financial Performance

12.11.4. Recent Initiatives

12.12. Jubilant Biosys

12.12.1. Company Overview

12.12.2. Product Offerings

12.12.3. Financial Performance

12.12.4. Recent Initiatives

12.13. DiscoverX Corporation

12.13.1. Company Overview

12.13.2. Product Offerings

12.13.3. Financial Performance

12.13.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms